- Home
- HRTX vs BDSX Comparison
HRTX vs BDSX Comparison
Compare HRTX & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- BDSX
- Stock Information
- Founded
- HRTX 1983
- BDSX 2005
- Country
- HRTX United States
- BDSX United States
- Employees
- HRTX 126
- BDSX N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- BDSX Precision Instruments
- Sector
- HRTX Health Care
- BDSX Health Care
- Exchange
- HRTX Nasdaq
- BDSX Nasdaq
- Market Cap
- HRTX 240.3M
- BDSX 194.9M
- IPO Year
- HRTX 1987
- BDSX 2020
- Fundamental
- Price
- HRTX $1.59
- BDSX $1.51
- Analyst Decision
- HRTX Strong Buy
- BDSX Strong Buy
- Analyst Count
- HRTX 3
- BDSX 4
- Target Price
- HRTX $5.67
- BDSX $3.08
- AVG Volume (30 Days)
- HRTX 6.2M
- BDSX 332.5K
- Earning Date
- HRTX 11-12-2024
- BDSX 11-01-2024
- Dividend Yield
- HRTX N/A
- BDSX N/A
- EPS Growth
- HRTX N/A
- BDSX N/A
- EPS
- HRTX N/A
- BDSX N/A
- Revenue
- HRTX $137,737,000.00
- BDSX $65,562,000.00
- Revenue This Year
- HRTX $13.10
- BDSX $46.97
- Revenue Next Year
- HRTX $18.76
- BDSX $30.43
- P/E Ratio
- HRTX N/A
- BDSX N/A
- Revenue Growth
- HRTX 12.13
- BDSX 48.92
- 52 Week Low
- HRTX $1.04
- BDSX $1.11
- 52 Week High
- HRTX $3.93
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- HRTX 50.28
- BDSX 48.94
- Support Level
- HRTX $1.53
- BDSX $1.24
- Resistance Level
- HRTX $1.88
- BDSX $1.43
- Average True Range (ATR)
- HRTX 0.17
- BDSX 0.10
- MACD
- HRTX 0.01
- BDSX 0.01
- Stochastic Oscillator
- HRTX 47.67
- BDSX 64.44
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.